Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech […]readmore
Tags : CureVac
Visby’s POC COVID-19 Test Receives the US FDA’s EUA for Use in CLIA Waived Settings Published: Feb 12, 2020 | Tags: Visby, POC, COVID-19, Test, Receives, US, FDA, EUA, Use, CLIA, […]readmore
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Shots: The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines […]readmore
Shots: CureVac to receive $90.14M up front, $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have […]readmore
Shots: Bayer to support the development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate, CVnCoV and will contribute its expertise and established infrastructure in numerous area Curevac will […]readmore
Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US […]readmore
Shots: The P-llb/lll HERALD trial will assess the safety and efficacy of CVnCoV (12 µg) in 35,000+ patients aged ≥18yrs. for the treatment of COVID-19 across EU and Latin America. […]readmore
Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US Published: Nov 13,2020 | Tags: Antigen Test, Digital, Launches, Portable, Qiagen, SARS-CoV-2, US GSK and Medicago Initiate P-II/III Study of […]readmore
Shots: The P-l study involves assessing CVnCoV in patients with COVID-19. The interim data showed that CVnCoV (2-12µg) was well tolerated and induced strong binding and neutralizing Ab responses to […]readmore